Erratum: Hepatocellular adenoma: What is new in 2008 (Hepatology International 10.1007/s12072-008-9075-0);Hepatocellular adenoma: What is new in 2008

Hepatology International

Volumn 2, Issue 3, 2008, Pages 316-321

  Bioulac Sage, Paulette ^a   Laumonier, Hervé ^b   Laurent, Christophe ^b   Zucman Rossi, Jessica ^c   Balabaud, Charles ^b  

^a HÔPITAL PELLEGRIN   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c INSERM   (France)

Author keywords

Adenomatosis; C reactive protein; Glutamine synthetase; Hepatocellular adenoma; Hepatocellular carcinoma; HNF 1 mutated adenoma; Inflammatory telangiectatic adenoma; Serum amyloid A; Catenin mutated adenoma

Indexed keywords

AMYLOID A PROTEIN; BETA CATENIN; C REACTIVE PROTEIN; FATTY ACID BINDING PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE AMMONIA LIGASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 7;

ADENOMATOSIS; CANCER RISK; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE OVEREXPRESSION; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; INFLAMMATION; LIVER ADENOMA; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; MATURITY ONSET DIABETES MELLITUS; NODULAR HYPERPLASIA; NONHUMAN; OBESITY; ORAL CONTRACEPTION; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SOMATIC MUTATION;

EID: 51049108991     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9089-7     Document Type: Erratum

References (30)

1. Bioulac-Sage P, Balabaud C, Bedossa P, Scoazec JY, Chiche L, Dhillon AP, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol 2007;46:521-7.
2. Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol 2008;48:163-70.
3. Paradis V, Laurent A, Flejou JF, Vidaud M, Bedossa P. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology 1997;26:891-5.
4. Bioulac-Sage P, Rebouissou S, Sa Cunha A, Jeannot E, Lepreux S, Blanc JF, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005;128:1211-8.
5. Bluteau O, Jeannot E, Bioulac-Sage P, Marques JM, Blanc JF, Bui H, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002;32:312-5.
6. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, et al. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996;84:575-85.
7. Rebouissou S, Imbeaud S, Balabaud C, Boulanger V, Bertrand-Michel J, Terce F, et al. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem 2007;282:14437-46.
8. Chen YW, Jeng YM, Yeh SH, Chen PJ. P53 gene and Wnt signaling in benign neoplasms: Beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 2002;36:927-35.
9. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, et al. Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. Hepatology 2006;43:515-24.
10. Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Jeannot E, et al. Hepatocellular adenomas subtype classification using molecular markers and immunohistochemistry. Hepatology 2007;46:740-8.
11. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95:8847-51.
12. Paradis V, Benzekri A, Dargere D, Bieche I, Laurendeau I, Vilgrain V, et al. Telangiectatic focal nodular hyperplasia: A variant of hepatocellular adenoma. Gastroenterology 2004;126:1323-9.
13. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996;384:455-8.
14. Bacq Y, Jacquemin E, Balabaud C, Jeannot E, Scotto B, Branchereau S, et al. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology 2003;125:1470-5.
15. Foster JH, Berman MM. The malignant transformation of liver cell adenomas. Arch Surg 1994;129:712-7.
16. Jeannot E, Poussin K, Chiche L, Bacq Y, Sturm N, Scoazec JY, et al. Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. Cancer Res 2007;67:2611-6.
17. Jeannot E, Wendum D, Paye F, Mourra N, de Toma C, Fléjou JF, et al. Hepatocellular adenoma displaying a HNF1alpha inactivation in a patient with familial adenomatous polyposis coli. J Hepatol 2006;45:883-6.
18. Chen PJ. Genetic mutation in hepatic adenoma: Seeing is believing. J Hepatol 2006;45:767-9.
19. Wanless IR, Albrecht S, Bilbao J, Frei JV, Heathcote EJ, Roberts EA, et al. Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: A new syndrome. Mod Pathol 1989;2:456-62.
20. Flejou JF, Barge J, Menu Y, Degott C, Bismuth H, Potet F, et al. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 1985;89:1132-8.
21. Monga SP. Hepatic adenomas: Presumed innocent until proven to be beta-catenin mutated. Hepatology 2006;43:401-4.
22. Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, et al. Glypican-3 expression in hepatocellular tumors: Diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006;37:1435-41.
23. Paradis V, Champault A, Ronot M, Deschamps L, Valla DC, Vidaud D, et al. Telangiectatic adenoma: An entity associated with increased body mass index and inflammation. Hepatology 2007;46:140-6.
24. Sa Cunha A, Blanc JF, Lazaro E, Mellottee L, Le Bail B, Zucman-Rossi J, et al. Inflammatory syndrome with liver adenomatosis: The beneficial effects of surgical management. Gut 2007;56:307-9.
25. van der Windt DJ, Kok NF, Hussain SM, Zondervan PE, Alwayn IP, de Man RA, et al. Case-orientated approach to the management of hepatocellular adenoma. Br J Surg 2006;93:1495-502.
26. Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol 2005;39:401-12.
27. Gibbs JF, Litwin AM, Kahlenberg MS. Contemporary management of benign liver tumors. Surg Clin North Am 2004;84:463-80.
28. Chiche L, Dao T, Salame E, Galais MP, Bouvard N, Schmutz G, et al. Liver adenomatosis: Reappraisal, diagnosis, and sErgical management: eight new cases and review of the literature. Ann Surg 2000;231:74-81.
29. Kim YI, Chung JW, Park JH. Feasibility of transcatheter arterial chemoembolization for hepatic adenoma. J Vasc Interv Radiol 2007;18:862-7.
30. Rocourt DV, Shiels WE, Hammond S, Besner GE. Contemporary management of benign hepatic adenoma using percutaneous radiofrequency ablation. J Pediatr Surg 2006;41:1149-52.